SCHERING-AG - ANALYSIS OF PATENTING 1992-1995

Schering AG, a company which pioneered oral contraceptives, still spec ialises in fertility control agents and related therapies. In this rev iew of the Company's recent patenting, steroids, prostaglandins and th romboxanes all feature prominently, but research is shown to have broa dened into such areas as cancer therapy, dermatology and antithromboti cs. Remarkably, no anti-infectives are under investigation. There are also well-characterised leukotriene B-4 and excitatory amino acid anta gonist projects, and the Company should now be in a position to identi fy compounds for preclinical investigation, thereby rectifying an imba lance in its current development pipeline.